Doug Baldridge is chair of Venable's Washington Litigation Group, encompassing the Washington, DC and Virginia offices. A first-chair litigator, Doug has tried numerous complex cases to verdict, including a victory on behalf of a generic drug maker in the first test of what limits may be placed on reverse payment antitrust deals in the wake of the U.S. Supreme Court's decision in FTC v. Actavis (In Re: Nexium (Esomeprazole) Antitrust Litigation). Doug represents major U.S. corporations in the pharmaceutical, technology, consumer products, fuel, and other industries; entertainers and other celebrities; real estate developers; publishers; shareholders; and other clients in high-stakes litigation.
Doug is widely recognized for his handling of legal and business issues, in matters involving:
Doug serves as general counsel for duPont Publishing, which distributes magazines under the duPont Registry brand in the United States and 54 other countries.
Doug has been recognized by a number of publications, including the National Law Journal, Law360, and Global Competition Review, as an "elite" trial lawyer and competition law "MVP."